Mammoth makes Dx CRISPR

How Mammoth plans to use CRISPR for faster, more adaptable diagnostics

Mammoth Biosciences emerged from stealth with an exclusive license to Jennifer Doudna’s CRISPR-based diagnostics technology, which could enable faster diagnosis of a range of diseases than PCR-based sequencing and culture-based techniques and be more adaptable than antibody-based diagnostics.

Several studies in the past year, including work from Doudna, have described how the biology of Cas12 and Cas13 family members positions the enzymes to extend CRISPR applications

Read the full 651 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE